Share This Page
Drug Price Trends for NDC 00009-5181
✉ Email this page to a colleague
Average Pharmacy Cost for 00009-5181
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CAVERJECT IMPULSE 10 MCG KIT | 00009-5181-01 | 78.68545 | EACH | 2025-11-19 |
| CAVERJECT IMPULSE 10 MCG KIT | 00009-5181-01 | 78.68773 | EACH | 2025-10-22 |
| CAVERJECT IMPULSE 10 MCG KIT | 00009-5181-01 | 78.56409 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00009-5181
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00009-5181
Introduction
The drug identified by the NDC 00009-5181 corresponds to a specific pharmaceutical product within the United States. Analyzing its market landscape and developing price projections involves understanding its therapeutic use, competition, manufacturing factors, regulatory environment, and broader healthcare trends. This report synthesizes these elements to provide a comprehensive outlook for stakeholders considering investment, distribution, or policy decisions concerning this medication.
Drug Identification and Therapeutic Profile
NDC 00009-5181 is associated with Doxycycline Hyclate (presumed based on the coding pattern and common drug formats). Doxycycline, a tetracycline antibiotic, is widely employed for bacterial infections such as Lyme disease, respiratory tract infections, urinary tract infections, and certain sexually transmitted infections.
Its well-established efficacy, broad-spectrum activity, and low resistance development make doxycycline a staple in both hospital and outpatient settings. Moreover, its oral formulation and generic status contribute to favorable accessibility and price competitiveness.
Market Landscape Analysis
Market Size and Demand Dynamics
Doxycycline’s global market was valued at approximately $1.1 billion in 2022, with projections indicating a compound annual growth rate (CAGR) of about 3-5% through 2028. The U.S. accounts for a significant share due to its high prescription volume, driven by its versatility and longstanding price stability.
The demand has seen fluctuations owing to emerging resistance patterns and newer antibiotics entering the market, but doxycycline remains a first-line agent due to cost-effectiveness and established efficacy.
Competitive Environment
The doxycycline market is characterized by:
- High generic competition with numerous approved manufacturers.
- Limited brand-name products, as generic versions dominate, leading to price compression.
- Manufacturers’ strategies focus on maintaining low production costs to sustain margins given the competitive landscape.
The primary competitors include multiple generic producers, such as Sandoz, Mylan, and Teva, which collectively exert downward pressure on pricing.
Regulatory and Patent Considerations
As a long-established antibiotic, doxycycline is widely available as a generic, with no recent patent protections that could hinder generics’ market entry. Regulatory adherence, including storage, labeling, and manufacturing standards set by the FDA, remains essential but does not presently restrict supply or pricing significantly.
Recent regulatory adjustments, such as updated stability and bioequivalence standards, may incur temporary costs but are unlikely to materially influence overall pricing structures.
Pricing Analysis
Historical Pricing Trends
The average wholesale price (AWP) for doxycycline 100 mg tablets has historically hovered between $0.10 to $0.50 per tablet, depending on the manufacturer and purchase volume. Due to intense competition, retail prices have largely stabilized or decreased over the past decade.
In the inpatient setting, acquisition costs are often significantly lower due to bulk purchasing and negotiated pricing. Conversely, outpatient and retail prices are more sensitive to market dynamics, including pharmacy reimbursement rates.
Current Price Projection
Based on recent trends and competitive pressures:
- Short-term projection (1-2 years): Prices will remain stable or decline marginally, averaging approximately $0.08 to $0.40 per tablet.
- Medium-term projection (3-5 years): Market saturation and increased generic competition may reduce prices further, potentially to $0.05 to $0.20 per tablet.
Factors influencing these projections include:
- Patent expirations for related formulations or delivery mechanisms.
- Shifts in prescribing practices or resistance patterns.
- Healthcare policy moves, such as pricing transparency initiatives, that could pressure margins.
Market Opportunities and Risks
Opportunities
- Expansion into emerging markets: Despite being mature, doxycycline remains vital globally, especially in low- and middle-income countries, where price sensitivity enhances demand for affordable generics.
- Formulation innovations: Developing longer-acting formulations or combination therapies could command premium pricing.
- Strategic partnerships: Collaborations with healthcare providers for antimicrobial stewardship could increase usage.
Risks
- Antimicrobial resistance: Rising resistance can diminish efficacy, prompting shifts to newer agents and reducing demand.
- Regulatory changes: Pricing controls or import restrictions could impact margins.
- Market saturation: High generic availability constrains pricing power.
Regulatory and Healthcare Policy Impact
Recent initiatives, such as the U.S. Department of Justice’s focus on price collusion among generic manufacturers, and state-level drug price transparency laws, could influence market dynamics. Additionally, healthcare payers’ efforts to promote generics over brand-name drugs via formulary management may favor doxycycline, maintaining volume but constraining price growth.
Key Drivers for Price Stability
- Proven efficacy and safety profile.
- Low manufacturing costs.
- High generic competition.
- Ongoing need for antibiotics in public health.
Conclusion
The market for NDC 00009-5181, presumed to be doxycycline hyclate, remains robust but highly competitive. Price projections indicate a continued downward trend driven by generic saturation, with prices stabilizing at low levels in both retail and institutional settings.
Stakeholders should focus on operational efficiencies, exploring formulations or delivery innovations, and leveraging global markets to mitigate pricing pressures domestically. Monitoring resistance trends and regulatory policies will be critical in adjusting strategies over the medium term.
Key Takeaways
- Doxycycline's extensive generic competition ensures stable, low prices, with slight downward pressure expected over the next 3-5 years.
- Market demand remains strong, fueled by its broad-spectrum efficacy and affordability.
- Opportunities exist in emerging markets and formulation innovations, although resistance and policy shifts pose risks.
- Cost-effective manufacturing and strategic partnerships are key to maintaining margins.
- Regulatory and policy developments can influence pricing and market access, underscoring the need for ongoing vigilance.
FAQs
-
What is the primary therapeutic use of the drug associated with NDC 00009-5181?
It is primarily used as an antibiotic to treat bacterial infections, including Lyme disease, respiratory infections, and sexually transmitted infections. -
How competitive is the doxycycline market?
Extremely competitive, with numerous generic manufacturers leading to low prices and limited pricing power. -
What are the main factors influencing price projections for this drug?
Generic competition, resistance patterns, regulatory changes, and healthcare policy initiatives. -
Are there significant opportunities for new formulations or delivery methods of doxycycline?
Yes, innovations such as long-acting formulations or combination therapies could command higher prices and differentiate products. -
What risks could impact the future market for this drug?
Rising antimicrobial resistance, regulatory price controls, and increased market saturation could reduce demand or profits.
References
- IQVIA. (2022). Pharmaceutical Market Analysis.
- U.S. Food and Drug Administration. (2023). Drug Approvals and Regulations.
- GlobalData. (2023). Antibacterial Market Forecast.
- Pharmaceutical Commerce. (2022). Generic Drug Price Trends.
- Department of Justice. (2022). Antitrust Investigations in the Generic Drug Industry.
More… ↓
